Navigation Links
AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
Date:12/3/2008

All amounts are in U.S. dollars

QUEBEC CITY, Dec. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, announces that it has completed the transaction under the previously announced purchase and sale agreement with Cowen Healthcare Royalty Partners, L.P. ("CHRP") relating to AEterna Zentaris' rights to royalties on future sales of Cetrotide(R) covered by its license agreement with Merck Serono. AEterna Zentaris received $52.5 million from CHRP at closing, less certain transaction costs. Under the terms of the agreement with CHRP, AEterna Zentaris would receive an additional payment of $2.5 million from CHRP contingent on 2010 net sales of Cetrotide(R) reaching a specified level.

About Cetrotide(R) (cetrorelix)

Cetrotide(R) (cetrorelix) was the first luteinizing hormone-releasing hormone (LHRH) antagonist treatment approved for in vitro fertilization. It is administered to women to prevent premature ovulation in order to increase fertility success rate. Developed in cooperation with Medicine Nobel-Prize winner, Professor Andrew Schally of Veterans Affairs, Miami, Florida, it was launched in Europe in 1999 and in the United States in 2001. Cetrotide(R) is currently marketed worldwide by Merck Serono, except for Japan where it is marketed by Nippon Kayaku and Shionogi.

Cetrorelix is also currently in a Phase 3 program in benign prostatic hyperplasia involving 1,500 patients in North America and Europe. First results are expected in Q3 2009 with an NDA filing to follow in 2010 and potential launch in 2011.

About Cowen Healthcare Royalty Partners

Cowen Healthcare Royalty Partners ("CHRP") is a global healthcare private equity firm with over $500 million in capita
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015 ... has announced the addition of Jain PharmaBiotech,s ... Markets and Companies"  to their offering.  ... disease remains a challenge in management. With ... in the seven major markets of the ...
(Date:5/28/2015)... May 28, 2015 ... has announced the addition of Jain ... Technologies, Markets and Companies"  to their ... report describes and evaluates animal biotechnology ... and pharmaceuticals as well as improvement ...
(Date:5/28/2015)... DUBLIN , May 27, 2015 ... addition of Jain PharmaBiotech,s new report "Cell ... their offering. This report describes and ... already started to play an important role in ... is replacing the old fashioned bone marrow transplants. ...
(Date:5/28/2015)... -- Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... institutional healthcare investors to purchase an aggregate of approximately ... at-the-market registered direct offering and a concurrent private placement ... Company entered into a definitive purchase agreement with these ... an aggregate of 3,000,000 shares of its common stock ...
Breaking Biology Technology:Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 3Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3
... CAMBRIDGE, Mass., April 17, 2012 Inspiration Biopharmaceuticals, Inc. ... Application (BLA) to the U.S. Food and Drug Administration ... factor IX (rFIX) protein for the treatment and prevention ... Based on the terms of its agreement with ...
... OLDSMAR, Fla., April 16, 2012  Cryo-Cell International, Inc. ... world,s first private cord blood bank to separate and ... the first quarter ended February 29, 2012.   ... many changes that are taking place at the Company," ...
... Md., April 16, 2012  The Maryland Technology Enterprise ... University of Maryland $75K Business Plan Competition ... has spurred the commercialization of university technologies and ... (Logo: http://photos.prnewswire.com/prnh/20101005/MTECHLOGO ) ...
Cached Biology Technology:Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B 2Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B 3Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B 4Cryo-Cell Reports Financial Results for First Quarter 2012 2Cryo-Cell Reports Financial Results for First Quarter 2012 3Cryo-Cell Reports Financial Results for First Quarter 2012 491 EnTERPreneurs Enter, Nine Remain 291 EnTERPreneurs Enter, Nine Remain 391 EnTERPreneurs Enter, Nine Remain 4
(Date:5/18/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
(Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
(Date:5/11/2015)... 2015  Through a well-rounded UAS delegation representing private industry, ... strong showing at AUVSI,s Unmanned 2015 conference last week in ... Ohio,s UAS industry met with over 200 hundred ... along the UAS ecosystem. "Our message is ... for Aerospace Rich Knoll . "If you want to ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... CA and TOKYO December 8, 2008 REGiMMUNE ... technologies and products for immune disorders, today announced that ... $12 million from the Japan Science and Technology Agency ... Under terms outlined in the five-year grant ...
... American Chemical Society (ACS) News Service Weekly PressPac with news ... News .,Please credit the individual journal or the American Chemical ... IS FOR IMMEDIATE RELEASE EXCEPT ARTICLE #5, which is embargoed ... PressPac Archive: ...
... Leuven, Belgium VIB researchers connected to the Katholieke Universiteit ... can detect nutrients. This happens in the same way − ... a message from a hormone. This finding can teach us ... can form the basis for new candidate targets for medicines. ...
Cached Biology News:American Chemical Society's Weekly PressPac -- Dec. 3, 2008 2American Chemical Society's Weekly PressPac -- Dec. 3, 2008 3American Chemical Society's Weekly PressPac -- Dec. 3, 2008 4American Chemical Society's Weekly PressPac -- Dec. 3, 2008 5American Chemical Society's Weekly PressPac -- Dec. 3, 2008 6American Chemical Society's Weekly PressPac -- Dec. 3, 2008 7American Chemical Society's Weekly PressPac -- Dec. 3, 2008 8Food can affect a cell in the same way hormones do 2
A camera based compact unit for high speed scanning of 2D barcoded tubes in a cluster rack. This reader has been designed to read both 96 and 48 tube rack configurations and be compatible with common...
... is a microprocessor controlled, high speed ... with exceptionally smooth operation make the ... involving fluorescence microscopy, ratio imaging, spectrophotometry, ... rapid and accurate aperture positioning. The ...
A compact, high-speed single tube reader unit designed for benchtop 2D barcode reading. The unit can be used with all of ABgene's 2D barcoded tubes, including the 2ml CryoCode tube....
PTFE/red rubber septum silver aluminum seal ,11 mm seal diam. ...
Biology Products: